peterschreiber.media Raymond James has started coverage of Tectonic Therapeutic ( NASDAQ: TECX ) with an outperform rating, citing its drug candidate TX45. The investment firm said it believes the company's relaxin mimetic drug candidate TX45 for the treatment of group 2 pulmonary hypertension is.
